SecBot SecBot

STTK

Shattuck Labs, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001680367 Biotech & Drug Discovery
$5.54 +0.05 (+0.91%)
Oct 26 4:00 PM ET · prev $5.49
Market cap
$562.0M
Small cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$15.50
+180% · range $10.00–19.00
Next earnings
Nov 10
in 15 days
1 year
+168.9%
from $2.06 · Oct 27
30 days
−13.8%
from $6.43
52-week range
$1.84–8.06
−31% from high · low Nov 13
Avg volume 20D
1.36M
shares / day
Short interest
10.95M
≈10.9% of shares · +60.8%
Days to cover
6.0
at average volume
Insider net
−$341.8K
3 buyers · 2 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus estimates of $-0.12. The…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders bought $250.0K at an average $4.00. 2 insiders sold $591.8K. Price is 38% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 22 added (1 new), 8 trimmed or exited. Largest new: Wellington Management Group $12.3M.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +60.8% to 10.95M shares. 6.0 days to cover, ≈10.9% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.3M
in new stakes
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD8,122,179$56.4M
BlackRock, Inc.DOUBLED3,935,810$27.3M
VANGUARD CAPITAL MANAGEMENT LLCADD3,207,865$22.3M
PRICE T ROWE ASSOCIATES INC /MD/ADD2,641,076$18.3M
WELLINGTON MANAGEMENT GROUP LLPNEW1,767,938$12.3M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,584,756$11.0M
STATE STREET CORPDOUBLED1,026,394$7.1M
GOLDMAN SACHS GROUP INCDOUBLED593,324$4.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy10Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +180%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026UBS
INITIATE
INITIATEBuy
Oct 2, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Oct 2, 2026Needham
MAINTAIN
MAINTAINBuy
Aug 24, 2026Raymond James
INITIATE
INITIATEStrong Buy
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 24, 2026JP Morgan
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$250.0K
bought · 3 insiders
$591.8K
sold · 2 insiders
+38.5%
vs their $4.00 cost
DateInsiderTypeValue
Jul 6, 2026
Shukla Abhinav A.
Chief Technical Officer
EXERCISE$43.4K
Jul 2, 2026
Shukla Abhinav A.
Chief Technical Officer
SELL$2.9K
Jul 2, 2026
Shukla Abhinav A.
Chief Technical Officer
EXERCISE$1.5K
Jul 1, 2026
Shukla Abhinav A.
Chief Technical Officer
EXERCISE$357.00
Jul 1, 2026
Shukla Abhinav A.
Chief Technical Officer
SELL$707.00
Jun 30, 2026
Pandite Arundathy N.
Chief Medical Officer
SELL$210.3K
Jun 30, 2026
Shukla Abhinav A.
Chief Technical Officer
EXERCISE$83.4K
Jun 30, 2026
Shukla Abhinav A.
Chief Technical Officer
SELL$165.4K

Earnings setup

Estimates
Nov 10
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
10,947,042
shares short
+60.8%
vs prior settlement
6.0
days to cover
≈10.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Short interest report
Short Interest: STTK up 61% to 10.9M shares
Settlement 2026-09-30 | Days to cover: 6.01 | ≈10.91% of shares outstanding (est.)
Aug 11, 2026 SEC
Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus estimates of $-0.12. The key…
8-K — Impact 7/10
Aug 11, 2026 SEC
Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus of -$0.12, with no revenue. The key…
PRESS-RELEASE — Impact 5/10
Jul 7, 2026 SEC
Two STTK insiders (Chief Medical Officer and Chief Technical Officer) sold a combined $213K in open-market sales over…
CLUSTER — Impact 3/10
Jul 6, 2026 Insider
Shukla Abhinav A. acquired via exercise 12,153 shares
Chief Technical Officer @ $3.57 ($43.4K)
Jul 2, 2026 Insider
Shukla Abhinav A. sold 410 shares
Chief Technical Officer @ $7.01 ($2.9K)
Jul 2, 2026 Insider
Shukla Abhinav A. acquired via exercise 410 shares
Chief Technical Officer @ $3.57 ($1.5K)
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — ADD
8,122,179 shares ($56.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
STTK Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 30, 2026
Short interest
Short Interest: STTK up 61% to 10.9M shares
Settlement 2026-09-30 | Days to cover: 6.01 | ≈10.91% of shares outstanding (est.)
Sep 15, 2026
Short interest
Short Interest: STTK up 22% to 6.8M shares
Settlement 2026-09-15 | Days to cover: 8.38 | ≈6.78% of shares outstanding (est.)
Sep 2, 2026
Press release
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage…
Aug 12, 2026
Earnings date
STTK Q2 2026 Earnings Scheduled — 2026-08-12
Aug 11, 2026
Earnings
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
– Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and…

SecBot reports

16 filings · 2 press releases · 3 bullish · 4 bearish · 9 neutral
All STTK filing & press-release reports (18)